HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like ...

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and ...

Voyager Therapeutics (VYGR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability ...

Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...

Altogen Labs is a preclinical research organization specializing in the testing and evaluation of novel pharmacological and biological treatments, including novel anticancer therapies, medical ...

PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS ...

Presentation of in vitro studies of RM-0256, a novel anti-PD-L1 antibody conjugated to IR700, which comprises a dual mode of photoimmunotherapy: depletion of PD-L1 expressing tumor cells and depletion ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...